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Abstract
Background: Myocardial infarction causes irreversible loss of cardiomyocytes and may lead to loss of ventricular
function, morbidity and mortality. Infarct size is a major prognostic factor and reduction of infarct size has therefore
been an important objective of strategies to improve outcomes. In experimental studies, glucagon-like peptide 1
and exenatide, a long acting glucagon-like peptide 1 receptor agonist, a novel drug introduced for the treatment
of type 2 diabetes, reduced infarct size after myocardial infarction by activating pro-survival pathways and by
increasing metabolic efficiency.
Methods: The EXAMI trial is a multi-center, prospective, randomized, placebo controlled trial, designed to evaluate
clinical outcome of exenatide infusion on top of standard treatment, in patients with an acute myocardial
infarction, successfully treated with primary percutaneous coronary intervention. A total of 108 patients will be
randomized to exenatide (5 μg bolus in 30 minutes followed by continuous infusion of 20 μg/24 h for 72 h) or
placebo treatment. The primary end point of the study is myocardial infarct size (measured using magnetic
resonance imaging with delayed enhancement at 4 months) as a percentage of the area at risk (measured using
T2 weighted images at 3-7 days).
Discussion: If the current study demonstrates cardioprotective effects, exenatide may constitute a novel
therapeutic option to reduce infarct size and preserve cardiac function in adjunction to reperfusion therapy in
patients with acute myocardial infarction.
Trial registration: ClinicalTrials.gov: NCT01254123
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Background
Myocardial infarction (MI) causes loss of cardiomyocytes
and may lead to loss of ventricular function, morbidity and
mortality. The impairment of left ventricular function may
lead to heart failure and death and has a major impact on
the quality of life of the patient. Infarct size is a major
prognostic factor after MI[1,2]. Reduction of infarct size
has therefore been an important objective of strategies to
improve clinical outcomes in patients that suffer acute MI.
It was previously demonstrated that early reperfusion
of the infarct related coronary artery, usually by primary
percutaneous intervention (PCI) limits myocardial
necrosis and improves clinical outcome in patients with
acute MI[3]. Despite adequate reperfusion, however,
most patients still suffer irreversible cardiomyocyte loss.
Ironically, part of this loss is induced by the reperfusion
itself. Reperfusion induces several biochemical and
metabolic changes, which lead to accelerated apoptosis
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of cardiomyocytes[4]. This phenomenon is referred to as
reperfusion injury[5].
Multiple strategies have been investigated to reduce
reperfusion injury. One of them is glucose-insulin-potas-
sium (GIK) infusion that has been postulated to possess
cytoprotective potential and has been investigated in
several clinical trials for cardioprotection in patients with
MI. Its efficacy is controversial, with some studies report-
ing a reduction in mortality in patients with acute MI
[6-8], whereas most studies demonstrated no beneficial
effect[9-11]. GIK infusion is complicated by volume over-
load, hypoglycemia and hyperkalemia. A promising alter-
native is Glucagon-Like Peptide (GLP)-1, a gut incretin
hormone, which is released by the gut in response to
nutrient intake[12]. It facilitates glucose dependent insulin
release and also exerts insulinomimetic actions via the
GLP-1 receptor, which is also expressed on cardiomyo-
cytes [13,14]. GLP-1 has been demonstrated to exert cardi-
oprotective effects in animal models by activating anti-
apoptotic signaling pathways and by increasing metabolic
efficiency[15]. In one small non-randomized clinical study,
21 patients with myocardial infarction and reduced myo-
cardial function were treated with GLP-1 infusion or pla-
cebo after successful PCI. GLP-1 treatment resulted in
significant improvement of cardiac function[16]. GLP-1
has a short half-life of minutes, being rapidly degraded by
dipeptidyl peptidase-4 (DPP-4). Therefore GLP-1 should
be administered continuously or administered together
with a DPP-4 inhibitor. DPP-4 resistant GLP-1 receptor
agonists, such as exendin-4 and its synthetic variant exena-
tide, have a longer half-life, making them more attractive
for clinical application[17]. Exenatide is currently used as
blood-glucose lowering-therapy in patients with type 2
diabetes. In a porcine model of ischemia and reperfusion
injury, exenatide reduced myocardial apoptosis and oxida-
tive stress. This resulted in reduced infarct size and pre-
served cardiac performance[18]. Also, in an isolated rat
heart model, exendin-4 provided cardioprotection. This
effect was abolished by using a GLP-1 receptor antagonist
[19]. These data suggest that exenatide exerts a direct car-
dioprotective effect via the GLP-1 receptor, rather than an
indirect effect via increased insulin levels.
The promising clinical results obtained with GLP-1 and
with exenatide in the experimental setting constituted the
rationale for the initiation of the EXAMI trial. This rando-
mized placebo controlled multi center study will assess the
cardioprotective effects of intravenous exenatide infusion
on top of standard treatment in patients with ST elevation
myocardial infarction undergoing primary PCI.
Methods
Overview
The EXAMI trial is a multi-center, prospective, rando-
mized, placebo controlled clinical trial, designed to
evaluate the safety and clinical efficacy of exenatide on top
of standard treatment, in patients with an acute MI, suc-
cessfully treated with PCI (http://www.clinicaltrials.gov;
unique identifier NCT01254123). The trial is conducted in
two Dutch hospitals: the VU University Medical Center in
Amsterdam, and the University Medical Center Utrecht.
The study was approved by the institutional ethical com-
mittee on human research and will be carried out in com-
pliance with the Helsinki Declaration. To be eligible for
participation in the trial, patients have to fit the inclusion
and exclusion criteria listed in Table 1. Initially, a pilot
study will be performed in the VU University Medical
Center Amsterdam, in order to assess the safety and feasi-
bility of exenatide infusion in patients with an acute MI.
Forty patients will be randomly assigned to treatment with
exenatide or placebo on top of standard treatment. An
interim analysis will take place after inclusion of these 40
patients. Also patients that initially receive study medica-
tion and are subsequently excluded based on exclusion
criteria during coronary angiogram or PCI, will be fol-
lowed for the registration of potential side effects. If signif-
icant negative side effects or significant differences are
observed in any of the endpoints in the disadvantage of
exenatide, the trial will be put on hold. If exenatide infu-
sion is considered safe, the study will be expanded to a
total of 108 patients to assess the cardioprotective effects
of exenatide following acute MI.
Patient enrolment and randomization
Patients with an acute ST elevation myocardial infarction
to be treated with primary PCI are potential candidates
for the study. Patients that are eligible for participation
are asked for informed consent. After informed consent,
patients are randomized to exenatide or placebo treat-
ment by using sealed envelopes. Only specially assigned
nurses will open the envelopes and will start study medi-
cation. All patients are also treated with aspirin, heparin
and clopidogrel according to the ESC guidelines. After
the start of administration of study medication a coron-
ary angiogram (CAG) and if possible primary PCI will be
performed. Patients can be excluded during CAG or pri-
mary PCI based on the criteria listed in table 1. The final
CAG will be performed for measurement of Thromboly-
sis in Myocardial Infarction (TIMI) frame count and
TIMI blush grade. During follow up, all patients will be
treated with aspirin, clopidogrel, aggressive lipid-lowering
treatment, ACE inhibitor or ARB, and beta-blocker,
unless contraindicated. The use of GPIIb/IIIa inhibitors
will be left to the discretion of the operator. The flow-
chart of the study design is shown in Figure 1.
Exenatide treatment protocol
Byetta injection pens (Amylin Pharmaceuticals, San Diego,
CA, USA) containing 1, 2 ml exenatide (concentration 0,
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25 mg/ml; 60 doses of 5 μg) will be obtained. Three doses
(15 μg) will be diluted in 49 ml saline and 1 ml Human
Serum Albumin (Cealb 200 g/L, 10 ml) to obtain an exe-
natide concentration of 0.30 μg/ml. Infusion will start
immediately after informed consent, just prior to PCI.
During the first 30 minutes it will be infused intravenously
at 33.33 ml/h (5 μg bolus in 30 minutes), followed by
intravenous infusion at 2.78 ml/h (20 μg/24 h) for 72
hours. New solutions will be made every 8 hours. Based
on experiences with healthy subjects, this is the maximum
well-tolerated intravenous dose.
Nausea is a side effect of exenatide as it slows gastric
emptying. It occurs in 40-50% of the patients, but is
usually mild, and severe nausea is reported in 3.5% of the
patients[20]. Nausea will be treated with metoclopramide
20 mg TID. If the nausea does not decrease in response
to metoclopramide, the dose of study medication will be
lowered to 50%. When serious side effects remain during
infusion, study medication will be stopped.
Blood analysis and blood glucose level monitoring
During hospital admission and follow up visits blood
analysis will be performed. An overview of blood analy-
sis during the study is listed in table 2. Blood glucose
levels will be monitored every 3 hours during the first
24 hours of study medication treatment, or when hypo-
glycemia is clinically suspected (Figure 2). When no
hypoglycemic (glucose level < 4 mmol/L) or hyperglyce-
mic (glucose level > 10 mmol/L) episodes occur during
the first 24 hours of study medication treatment, blood
glucose levels will be monitored 4 times a day until the
end of admission. In case of hypoglycemia patients will
be treated with 100 ml glucose 50% infusion and subse-
quently with glucose 5% 1 L/24 hours. During a
Table 1 Inclusion and exclusion criteria
Inclusion
criteria
> 18 and < 80 years of age
First myocardial infarction
ST elevation of more than one mm in at least 2 separate leads on the electrocardiogram (ECG)
Delay between onset of sustained chest pain and PCI < 6 hours.
Exclusion
criteria
Cardiac rhythm is other than normal sinus rhythm.
Patient in Killip class 3 or 4 of heart failure
Cardiogenic shock defined as sustained systolic blood pressure ≤ 80 mmHg despite fluid hydration.
Post cardiac resuscitation
Need for intra aortic balloon counterpulsation therapy
The patient is unable to hold his/her breath for up to 20 seconds due to age or concomitant illness
Former PCI performed
No re-canalization achieved of the occluded coronary artery
Culprit not in segment 1, 2, 3, 6, 7, 11, 12, 13 of the coronary artery
No definite culprit
More than one occluded vessel, or a more than 70% stenosis by visual assessment in a non-culprit vessel.
TIMI 3 flow in culprit lesion at presentation
Decreased renal function eGFR < 30 mL/min/1.73 m2
Any contraindication for MRI
Metal fragments in eye, head, ear, skin or shoulder.
Swann-Ganz catheter.
Known pre-existing left ventricular dysfunction measured by any technique (ejection fraction < 45% prior to current admission for
myocardial infarction)
Prior myocardial infarction
Prior coronary artery bypass grafting
Moderate to severe cardiac valve disease
Stroke or transient ischemic attack within the previous 24 hours
Serious known concomitant disease with a life expectancy of less than one year
Follow up impossible
Previous participation in a trial within the previous 30 days
Known type I Diabetes
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hypoglycemic period blood glucose levels will be
assessed every hour until blood glucose levels are > 4
mmol/L. During hypoglycemic periods study medication
will be continued.
Patients who are hyperglycemic at presentation will be
treated with intravenous actrapid as long as necessary to
maintain blood glucose levels between 4 and 8 mmol/L.
Actrapid will be started at a dose of 1 unit/hour and the
Figure 1 Flowchart of the study design. This figure illustrates the study design. A total of 108 patients will be randomized to Exenatide (n =
54) or placebo (n = 54) infusion. The treatment will be initiated just prior to PCI and will be continued for 72 hours. Echocardiography and MRI
will be performed during hospital admission (within 2-7 days for echo and within 3-7 days for MRI) and at 4 months follow up.
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Table 2 Blood analysis during the study
Laboratory measurements on admission: ESR; CRP; hemoglobin; hematocrit; platelet count; leucocytes; leukocyte differential; sodium;
potassium; creatinin; urea; AST; ALT; LDH; bilirubin; CK; CK-MB; troponin; total cholesterol; LDL
cholesterol; HDL cholesterol; plasma glucose; HbA1c; NT-proBNP; albumin; homocysteine;
Lipoproteine(a); Insulin; C-peptide; Free Fatty Acids; APTT; INR;
Routine laboratory measurements (every
morning at 9:00)
CRP, hemoglobin; hematocrit; platelet count; leucocytes; sodium; potassium; creatinin; exenatide
serum level (during duration of study medication), insulin, C-peptide.
Other laboratory measurements On the fourth day after admission a triglyceride level and a blood glucose level will be obtained
in the fasting state. Exenatide serum levels, insulin and C-peptide will be measured 4 h after
initiation of treatment.
Laboratory measurements at follow up visit at
1 month and 4 months
ESR; CRP; hemoglobin; hematocrit; platelet count; leucocytes; sodium; potassium; creatinin; AST;
ALT; LDH; total cholesterol; LDL cholesterol; HDL cholesterol; blood glucose level; HbA1c; NT-
proBNP; albumine; Lipoproteine (a)
Figure 2 Blood glucose monitoring and control. The blood glucose levels are targeted between 4-10 mmol/L. Hypoglycemia will be treated
with intravenous glucose infusion and hyperglycemia with intravenous insulin infusion as indicated in the flowchart.
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dose will be adjusted according to blood glucose levels
that will be checked every three hours.
Mild to moderate hypoglycemia is expected in
approximately 5% of the patients, severe hypoglycemia is
not expected[20].
Magnetic Resonance Imaging (MRI)
Three to 7 days and 4 months after primary PCI a car-
diac MRI with delayed contrast enhancement (DCE) will
be performed to assess left ventricular function and
infarction size. The first MRI is performed to visualize
myocardial edema, i.e. the area at risk. The second MRI
is preformed to measure myocardial fibrosis, i.e. infarct
area. Doing so, infarct size can be measured as a percen-
tage of the area at risk. Patients are studied on a clinical
1, 5 Tesla scanner with a cardiac phased array receiver
surface coil placed on the thorax.
ECG-gated cine MR images are obtained during
repeated breath-holds in the 3 standard long axis views (4-
, 3- and 2-chamber view). Additional short axis slices are
acquired covering the entire left ventricle to examine
regional and global left ventricular function. T2-weighted
imaging will be acquired in long and short axis views and
will be used to estimate the area at risk[21-23]. During
intravenous injection of 0, 10 mmol/kg gadolinium-
diethyltriaminepenta-acetic acid, first-pass perfusion ima-
ging is performed. Delayed contrast enhanced images are
acquired 10 minutes post-contrast to identify the location
and extent of myocardial infarction.
All images are stored on a database where it will be for-
warded for later blinded analysis. The MRI data are ana-
lyzed using a software package (Mass, Medis, Leiden, the
Netherlands). On the short axis cine slices, the endocardial
and epicardial borders are outlined manually in end-dia-
stolic and end-systolic images, excluding trabeculae and
papillary muscles. Assessment of global left ventricular
function is obtained by calculating left ventricular
volumes, mass, and ejection fraction using the summation
of slice method multiplied by slice distance. For analysis of
segmental myocardial function, each short axis slice is
divided in 12 equiangular segments, starting at the poster-
ior septal insertion of the right ventricle. Segmental wall
thickening is expressed in absolute values (end-diastolic
wall thickness subtracted from end-systolic wall thickness
[in millimeters]) and relative values (absolute wall thicken-
ing divided by end-diastolic wall thickness [%]). Areas of
hyperenhancement are outlined, including central dark
zones of microvascular obstruction, allowing the calcula-
tion of total infarct size by summation of all slice volumes
of hyperenhancement.
Echocardiography
Two to 7 days and 4 months after primary PCI, trans-
thoracic echocardiography will be performed to measure
global and regional cardiac function, using the iE33 ultra-
sound system (Philips Medical Systems, Andover, MA,
USA) equipped with a S5-2 phased array (1 to 5 MHz
broadband) transducer (Philips Medical Systems, And-
over, MA, USA). A systematic imaging protocol will be
performed, consisting of parasternal long-axis, short-axis
and 4-, 2-, and 3-chamber apical views, closely following
current guidelines. Global function of the left ventricle
will be assessed with biplane Simpson’s method. Global
right ventricular function will be measured with the func-
tional parameter tricuspid annular plane systolic excur-
sion (TAPSE). Mitral, tricuspid, pulmonary and aortic
valve will be assessed with color Doppler, measuring fill-
ing times, E- and A-top of the mitral valve and valvular
function. In addition, the diastolic left ventricular func-
tion will be assessed with coded tissue Doppler imaging
measuring peak tissue velocity during early diastole (E’)
at the basal left ventricular septum and lateral wall.
Finally, using the same ultrasound system equipped with
a X3-1 matrix-array transducer (Philips Medical Systems,
Andover, MA, USA) a complete real-time 3-dimensional
echo dataset will be obtained for blinded off-line analysis
of global and regional left ventricular function.
Follow up
All patients visit our outpatient clinic at 6 weeks and at
4 months after primary PCI. The visits consist of clinical
evaluation, blood analysis, and 12-lead electrocardio-
gram. Major cardiovascular events (death, myocardial
re-infarction, coronary artery bypass grafting, repeat
PCI) will be documented. Furthermore, cardiac arrhyth-
mias, heart failure, repeat coronary angiography, stroke,
and hospital admission) are documented. At 4 months a
second MRI and echocardiography will be performed to
assess cardiac function and infarct size.
End points
The primary endpoint of the study is myocardial infarct
size as a percentage of the area at risk (i.e. the perfusion
territory of the infarct related coronary artery) as mea-
sured by MRI. The area at risk is measured 3-7 days
after primary PCI and myocardial infarct size is mea-
sured 4 months after primary PCI. All secondary end-
points are indicated in table 3.
Sample Size
Myocardial infarct size as a percentage of the area at risk
will be the primary endpoint of the study. With a power
of 0.9 and an alpha error of 0.05, and with an anticipated
15% reduction in myocardial infarct size in the treatment
arm considered clinically relevant, 48 patients per treat-
ment arm have to be enrolled. To allow for dropout of
10% (based on previous experience), a total of 108
patients will be enrolled.
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Statistical Analysis
The study results will be evaluated based on intention to
treat analysis. Depending on the distribution of continu-
ous outcomes, independent samples t-test or Mann-
Whitney U test will be used as appropriate. Binary end
points will be compared using Fisher exact probability
test. For survival and clinical events, Kaplan Meijer
curves will be displayed and comparison of the curves
will be done using log rank testing based on a propor-
tional hazards model.
Conclusion and implications
The EXAMI study, as outlined above, is a randomized
clinical trial to investigate the cardioprotective proper-
ties of exenatide in patients with acute MI undergoing
primary PCI, by means of measuring final infarct size
compared to area at risk as measured with MRI. If
reduction in infarct size is accomplished, exenatide may
constitute a valuable therapeutic auxiliary for reperfu-
sion therapy in patients with acute MI.
Trial status
Currently including patients
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